Opportunities for use of neuroimaging in de-risking drug development and improving clinical outcomes in psychiatry: an industry perspective

HIGHLIGHTS

• What: Of note, while here the authors focus on the development and deployment of more widely used pharmacological therapies, the same concepts can apply to other interventions, such as brain stimulation or psychosocial interventions. The two current principal uses, which make up the primary focus of this piece, are as pharmacodynamic or target engagement measures to de-risk drug development and as patient stratification or selection measures to enrich clinical trials and improve clinical care outcomes (see Fig 1). Impact of commercial and clinical feasibility on design of clinical trials Unlike in academia, where the outcome of . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.